Antisense Modulation of Both Exonic and Intronic Splicing Motifs Induces Skipping of a DMD Pseudo-Exon Responsible for X-Linked Dilated Cardiomyopathy
- 1 September 2010
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 21 (9) , 1137-1146
Abstract
Antisense-mediated exon skipping has been actively investigated as a treatment strategy for subsets of Duchenne muscular dystrophy mutations. This approach is based on targeting specific splicing motifs that interfere with the spliceosome assembly resulting in an in-frame deletion of a deleterious mutation. In this study, Rimessi et al. use a variety of in vitro strategies to examine the role of intronic splicing sequences with the goal of designing improved exon skipping-mediated therapeutic approaches. Antisense-mediated exon skipping has proven to be efficacious for subsets of Duchenne muscular dystrophy mutations. This approach is based on targeting specific splicing motifs that interfere with the spliceosome assembly by steric hindrance. Proper exon recognition by the splicing machinery is thought to depend on exonic splicing enhancer sequences, often characterized by purine-rich stretches, representing potential targets for antisense-mediated exon skipping. We identified and functionally characterized two purine-rich regions located within dystrophin intron 11 and involved in splicing regulation of a pseudo-exon. A functional role for these sequences was suggested by a pure intronic DMD deletion causing X-linked dilated cardiomyopathy through the prevalent cardiac incorporation of the aberrant pseudo-exon, marked as Alu-exon, into the dystrophin transcript. The first splicing sequence is contained within the pseudo-exon, whereas the second is localized within its 3′ intron. We demonstrated that the two sequences actually behave as splicing enhancers in cell-free splicing assays because their deletion strongly interferes with the pseudo-exon inclusion. Cell-free results were then confirmed in myogenic cells derived from the patient with X-linked dilated cardiomyopathy, by targeting the identified motifs with antisense molecules and obtaining a reduction in dystrophin pseudo-exon recognition. The splicing motifs identified could represent target sequences for a personalized molecular therapy in this particular DMD mutation. Our results demonstrated for the first time the role of intronic splicing sequences in antisense modulation with implications in exon skipping-mediated therapeutic approaches.Keywords
This publication has 49 references indexed in Scilit:
- Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating MechanismsMolecular Therapy, 2009
- Antisense-mediated exon skipping: A versatile tool with therapeutic and research applicationsRNA, 2007
- Therapeutic Modulation of DMD Splicing by Blocking Exonic Splicing Enhancer Sites with Antisense OligonucleotidesAnnals of the New York Academy of Sciences, 2006
- Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame ruleMuscle & Nerve, 2006
- Splicing in action: assessing disease causing sequence changesJournal of Medical Genetics, 2005
- Dystrophinopathy caused by mid-intronic substitutions activating cryptic exons in the DMD geneNeuromuscular Disorders, 2004
- Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More SenseThe American Journal of Human Genetics, 2004
- Mechanisms of Alternative Pre-Messenger RNA SplicingAnnual Review of Biochemistry, 2003
- Regulation of alternative splicing by SRrp86 through coactivation and repression of specific SR proteinsRNA, 2002
- Identification of a Bidirectional Splicing Enhancer: Differential Involvement of SR Proteins in 5′ or 3′ Splice Site ActivationMolecular and Cellular Biology, 1999